期刊文献+

环磷酰胺联合伊马替尼治疗难治性系统性硬化病一例 被引量:2

原文传递
导出
摘要 患者女,65岁,2010年初无明显诱因下出现颜面部、双手、前臂、双小腿皮肤变硬,张口受限,同时有双肩关节、双手指间关节及双膝关节酸痛,伴双下肢浮肿;查血自身抗体显示:ANA:1:1280,抗Sc1-70抗体(++);胸部CT示“间质性肺炎”。诊断为SSc。2010年6月起予以“泼尼松片30m州、白芍总苷(帕夫林)片、青霉胺、积雪苷、酮替芬药物口服联合环磷酰胺O.8朋”冲击治疗,并予以每月1次大功率长波紫外线(UVA)硬化处皮肤照射治疗(先后共13次),但患者症状进行性加重,逐渐出现气促,活动后明显,皮肤硬化也逐渐加重,期间上述药物持续使用(泼尼松逐渐减量至10m∥d,累计环磷酰胺总量为8.8g)。至2012年2月患者平走即有气促,平素需吸氧,改良的Rodnan皮肤厚度评分(modified rodnan skin score,MRSS)19分,不吸氧下血气分析示血氧饱和度(SpO2)仅90%,超声心动图测肺动脉收缩压为26mmHg(1mmHg=0.133kPa),ESR:19mrrdlh,CRP:7.2mg/L,胸部高分辨率CT(HRCT)示两侧肺纹理增多、增粗、紊乱,两侧胸膜下可见网格状阴影。气管居中,纵隔居中,内见小淋巴结。双侧胸腔未见积液。两侧胸膜增厚。考虑肺间质纤维化进展较快,于2012年2月起加用“伊马替尼0.1g,每日2次”治疗,同时继续“泼尼松10mCd+每3个月1次环磷酰胺0.8g冲击治疗”。2012年10月起患者全身皮肤发硬较前明显好转,胸闷气促较前改善,MRSS评分9分,不吸氧下SpO2升至95%,超声心动图测肺动脉收缩压25mmHg,ESR:15mm/1h,CRP:8.5mg/L,胸部HRCT示两肺间质性改变,对比2012年1月8日CT片呈好转趋势,两侧胸膜增厚。期间患者仅出现轻微的胃肠道反应,未出现骨髓抑制、肝损害、肾损害、充血件心力衰蝎等药物不良反府.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2014年第8期577-578,共2页 Chinese Journal of Rheumatology
  • 相关文献

参考文献10

  • 1Trojanowska M. What did we learn by studying scleroderma fibroblasts?[J]. Clin Exp Rheumatol, 2004, 22" S59-63.
  • 2Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myel- ogenous leukemia[J]. Clin Cancer Res, 2002, 8: 935-942.
  • 3Sabnani I, Zucker M J, Rosenstein El), et al. A novel thera- peutic approach to the treatment of scleroderma-associated pul- monary complications : safety and efficacy of combination therapy with imatinib and cyclophosphamide [J]. Rheumatology, 2009, 48 : 49-52.
  • 4Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate re- duces production of extracellular matrix and prevents develop- ment of experimental dermal fibrosis[J]. Arthritis Rheum, 2007, 56: 311-322.
  • 5Van Daele PL, Dik WA, Thio HB, et al. Is imatinib mesylate apromising drug in systemic clemsis?[J]. Arthritis Rheum, 2008, 58 : 2549-2552.
  • 6Khanna D, Saggar R, Clements P, et al. Open labeled study of imatinib mesylate (Gleevec) in the treatment of systemic scle- rosis-associated active interstitial lung disease (SSC-ILD): pre- liminary results[J]. Ann Rheum Dis, 2009, 68: Sl17.
  • 7Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclero- sis:results of a I-year, phase IIa, single-arm, open-label clinical trial[J]. Ann Rheum Dis, 2011, 70: 1003-1009.
  • 8Guo L, Chen XX, Gu YY, et al. Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chi- nese patients and literature review. Clin Rheumatol, 2012, 31: 1395-1400.
  • 9Bournia VK, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib [J]. Semin Arthritis Rheum, 2013, 42: 377-390.
  • 10Chung L, Fiorentino DF, Benbark MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis [J]. Arthritis Rheum, 2009, 60: 584-591.

同被引文献4

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部